Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 121, 2001 - Issue 8
Submit an article Journal homepage
9
Views
0
CrossRef citations to date
0
Altmetric
Research Article

What's New in the Biology and Treatment of Undifferentiated Carcinoma of Nasopharyngeal Type?

Antonino Carbone, Riccardo Dolcetti, Ashok R. Shaha, Annunziata Gloghini, Roberto Molinari, Alessandra Rinaldo, Mauro Boiocchi, William I. Wei, Alfio Ferlito Experimental Oncology, National Cancer Institute, IRCCS, Aviano, Italy
Pages 884-895 | Published online: 08 Jul 2009

  • Vasef MA, Ferlito A, Weiss LM. Nasopharyngeal carcinoma, with emphasis on its relationship to EpsteinBarr virus. Ann Otol Rhinol Laryngol 1997; 106: 348-56.
  • Sham JST, Wei WI, Tai PTH, Choy D. Multiple malignant neoplasms in patients with nasopharyngeal carcinoma Oncology 1990; 47: 471-4.
  • Cooper JS, Scott C, Marcial V, et al. The relationship of nasopharyngeal carcinomas and second independent malignancies based on Radiation Therapy Oncology Group Experience. Cancer 1991; 67: 1673-7.
  • Skinner DW, Van Hassett CA, Tsao SY. Nasopharyngeal carcinoma: modes of presentatioa Ann Otol Rhinol Laryngol 1991; 100: 544-51.
  • Wells C. Ancient Egyptian pathology. J Laryngol Otol 1963; 77: 261-5.
  • Jackson C. Primary carcinoma of the nasopharynx. A table of cases. JAMA 1901; 37: 371-7.
  • Shanmugaratnam K, Sobin LH. Histological typing of tumours of the upper respiratory tract and ear. World Health Organization-international histological classification of tumours, 2nd edn. Berlin: Springer-Verlag, 1991.
  • Regaud C, Reverchon L. Sur un cas d'épithélioma epidermoide developpé dans le massif maxillaire supérieure, et endu aux teguments de la face, aux cavities buccale, nasale-et orbitaire, ainsi que aux ganglions de cou, gueri par la curiethérapie. Rev Laryngol Otol Rhinol (Bord) 1921; 42: 369-78.
  • Schmincke A. Über lymphoepitheliale Geschwülste. Beitr Pathol Anat AlIg Pathol 1921; 68: 161-70.
  • Micheau C. What's new in histological classification and recognition of naso-pharyngeal carcinoma (N.P.C.). Pathol Res Pract 1986; 181: 249-53.
  • International Agency for Research on Cancer. EpsteinBarr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 70. Lyon: WHO, 1997.
  • Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. MoI Pathol 2000; 53: 248-54.
  • Fandi A, Yanes B, Taamma A, et al. [Undifferentiated carcinoma of the nasopharynx: epidemiological clinical and therapeutic aspects]. Bull Cancer 1994; 81: 571-86.
  • Ambinder RF, Robertson KD, Moore SM, Yang J. Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin Cancer Biol 1996; 7: 217-26.
  • Shanmugaratnam K. Histological typing of nasopharyngeal carcinoma. In: De-Thé G, Ito Y, eds. Nasopharyngeal carcinoma: etiology and control International Agency for Research on Cancer Scientific Publications No. 20. Lyon: IARC, 1978: 3-12.
  • Weiland LH. The histopathological spectrum of nasopharyngeal carcinoma. In: De-Thé G, Ito Y, eds. Nasopharyngeal carcinoma: etiology and control International Agency for Research on Cancer Scientific Publications No. 20. Lyon: IARC, 1978: 41-50.
  • Lennert K, Kaiserling E, Mazzanti T. Diagnosis and differential diagnosis of lymphoepithelial carcinoma in lymph nodes: histological, cytological and electron-microscopic findings. In: De-Thé G, Ito Y, eds. Nasopharyngeal carcinoma: etiology and control International Agency for Research on Cancer Scientific Publications No. 20. Lyon: IARC, 1978: 51-64.
  • Carbone A, Micheau C. Pitfalls in microscopic diagnosis of undifferentiated carcinoma of nasopharyngeal type (lymphoepithelioma). Cancer 1982; 50: 1344-51.
  • Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young LS. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol 1995; 147: 1152-60.
  • Goldenberg D, GoIz A, Netzer A, et al. Epstein-Barr virus and cancers of the head and neck. Am J Otolaryngol 2001; 22: 197-205.
  • Raab-Traub N, Flynn K, Pearson G, et al. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer 1987; 39: 25-9.
  • Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1995; 146: 1355-67.
  • Ferlito A, Weiss LM, Rinaldo A, et al. Lymphoepithelial carcinoma of the larynx, hypopharynx, and trachea. Ann Otol Rhinol Laryngol 1997; 106: 437-44.
  • Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation, Cell 1986; 47: 883-9.
  • Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985; 35: 35-42.
  • Greenspan JS, Greenspan D, Lennette ET, et al. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med 1985; 313: 1564-71.
  • Gratama JW, Oosterveer MA, Zwaan FE, Lepoutre J, Klein G, Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sei USA 1988; 85: 8693-6.
  • Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. Epstein-Barr virus (EBV) infection in infectious mononucleosis virus latency, replication and phenotype of EBV-infected cells. J Pathol 1997; 182: 151-9.
  • Faulkner GC, Burrows SR, Khanna R, Moss DJ, Bird AG, Crawford DH. X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol 1999; 73: 1555-64.
  • Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 1998; 9: 395-404.
  • Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994; 68: 7374-85.
  • Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sei USA 1984; 81: 3806-10.
  • Longnecker R. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res 2000; 79: 175-200.
  • Speck P, Haan KM, Longnecker R. Epstein-Barr virus entry into cells. Virology 2000; 277: 1-5.
  • Burgos JS, Vera-Sempere FJ. Immunohistochemical absence of CD21 membrane receptor in nasopharyngeal carcinoma cells infected by Epstein-Barr virus in Spanish patients. Laryngoscope 2000; 110: 2081-4.
  • Imai S, Nishikawa J, Takada K. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 1998; 72: 4371-8.
  • Tao Q, Srivastava G, Chan AC, Chung LP, Loke SL, Ho FC. Evidence for lytic infection by Epstein-Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals. J Med Virol 1995; 45: 71-7.
  • Holmgren L, Szeles A, Rajnavolgyi E, et al. Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood 1999; 93: 3956-63.
  • Sixbey JW, Yao QY. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science 1992; 255: 1578-80.
  • Lin CT, Lin CR, Tan GK, Chen W, Dee AN, Chan WY. The mechanism of Epstein-Barr virus infection in nasopharyngeal carcinoma cells. Am J Pathol 1997; 150: 1745-56.
  • Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17: 1-7.
  • Li QX, Young LS, Niedobitek G, et al. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 1992; 356: 347-50.
  • Sixbey JW, Vesterinen EH, Nedrud JG, Raab-Traub N, Walton LA, Pagano JS. Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature 1983; 306: 480-3.
  • Sam CK, Brooks LA, Niedobitek G, Young LS, Prasad U, Rickinson AB. Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. Int J Cancer 1993; 53: 957-62.
  • Wu TC, Mann RB, Epstein JI, et al. Abundant expression of EBERl small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol 1991; 138: 1461-9.
  • Pathmanathan R, Prasad U, Sadler R, Flynn K, RaabTraub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 333: 693-8.
  • Yao Y, Minier HA, Chen X, Reynolds GM, Bromley M, Arrand JR. Heterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma. Int J Cancer 2000; 88: 949-55.
  • Cheung F, Pang SW, Hioe F, Cheung KN, Lee A, Yau TK. Nasopharyngeal carcinoma in situ: two cases of an emerging diagnostic entity. Cancer 1998; 83: 1069-73.
  • Luka J, Deeb ZE, Hartmann DP, Jenson B, Pearson GR. Detection of antigens associated with Epstein-Banvirus replication in extracts from biopsy specimens of nasopharyngeal carcinomas. J Natl Cancer Inst 1988; 80: 1164-7.
  • Young LS, Dawson CW, Clark D, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988; 69: 1051-65.
  • Lung ML, Chan KH, Lam WP, et al. In situ detection of Epstein-Barr virus markers in nasopharyngeal carcinoma patients. Oncology 1989; 46: 310-7.
  • Cochet C, Martel-Renoir D, Grunewald V, et al. Expression of the Epstein-Barr virus immediate early gene, BZLFl, in nasopharyngeal carcinoma tumor cells. Virology 1993; 197: 358-65.
  • Trumper PA, Epstein MA, Giovanella BC, Finerty S. Isolation of infectious EB virus from the epithelial tumour cells of nasopharyngeal carcinoma. Int J Cancer 1977; 20: 655-62.
  • Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. MoI Pathol 2000; 53: 238-47.
  • Cohen JI. Epstein-Barr virus infectioa N Engl J Med 2000; 343: 481-92.
  • Komano J, Maruo S, Kurozumi K, Oda T, Takada K. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 1999; 73: 9827-31.
  • Wilson JB, Levine AJ. The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. Curr Top Microbiol Immunol 1992; 182: 375-84.
  • Niedobitek G, Young LS, Sam CK, Brooks L, Prasad U, Rickinson AB. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol 1992; 140: 879-87.
  • Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNAl, LMPl, and LMP2 transcripts. J Virol 1992; 66: 268997.
  • Xu J, Ahmad A, D'Addario M, et al. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J Immunol 2000; 164: 2815-22.
  • Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 831-40.
  • Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990; 344: 777-80.
  • Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ. Expression of the BNLF-1 oncogene of EpsteinBarr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990; 61: 1315-27.
  • Fahraeus R, Rymo L, Rhim JS, Klein G. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 1990; 345: 447-9.
  • Niedobitek G, Fahraeus R, Herbst H, et al. The Epstein-Barr virus encoded membrane protein (LMP) induces phenotypic changes in epithelial cells. Virchows Arch B Cell Pathol Incl MoI Pathol 1992; 62: 55-9.
  • Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995; 69: 4390-8.
  • Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 1996; 70: 8653-9.
  • Eliopoulos AG, Stack M, Dawson CW, et al. EpsteinBarr virus-encoded LMPl and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 1997; 14: 2899-916.
  • Eliopoulos AG, Rickinson AB. Epstein-Barr virus: LMPl masquerades as an active receptor. Curr Biol 1998; 8: R196-8.
  • Eliopoulos AG, Dawson CW, Mosialos G, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996; 13: 2243-54.
  • Hu LF, Chen F, Zhen QF, et al. Differences in the growth pattern and clinical course of EBV-LMPl expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer 1995; 31A: 658-60.
  • Yoshizaki T, Sato H, Furukawa M, Pagano JS. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sei USA 1998; 95: 3621-6.
  • Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000; 89: 715-23.
  • Lin SY, Tsang NM, Kao SC, et al. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head Neck 2001; 23: 194-200.
  • Frech B, Zimber-StroM U, Yip TT, Lau WH, MuellerLantzsch N. Characterization of the antibody response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma. J Gen Virol 1993; 74: 811-8.
  • Lennette ET, Winberg G, Yadav M, Enblad G, Klein G. Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer 1995; 3IA: 1875-8.
  • Scholle F, Longnecker R, Raab-Traub N. Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal Src kinase. J Virol 1999; 73: 4767-75.
  • Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59: 1188-91.
  • Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999; 59: 5452-5.
  • Lo YM, Leung SF, Chan LY, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000; 60: 2351-5.
  • Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000; 60: 6878-81.
  • Zong YS, Sham JST, Ng MH, et al. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 1992; 69: 3-7.
  • Sham JST, Wei WI, Zong YS, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet 1990; 335: 371 -4.
  • Fandi A, Altun M, AzIi N, Armand JP, Cvitkovic E. Nasopharyngeal cancer epidemiology, staging, and treatment. Semin Oncol 1994; 21: 382-97.
  • Boussen H, Cvitkovic E, Wendung JL, et al. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouraciL J Clin Oncol 1991; 9: 1675-81.
  • Bachouchi M, Cvitkovic E, AzIi N, et al. High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. J Natl Cancer Inst 1990; 82: 616-20.
  • AzIi N, Fandi A, Bachouchi M, et al. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sei Am 1995; 1: 222.
  • Fandi A, Bachouchi M, AzIi N, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000; 18: 1324-30.
  • International Nasopharynx Cancer Study Group. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, MO) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 1996; 35: 463-9.
  • El Guedari B. Final results of the VUMCA I randomized trial comparing neoadjuvant chemotherapy (CT) (BEC) plus radiotherapy (RT) to RT alone in undifferentiated nasopharyngeal carcinoma (UCNT). Proc Am Soc Clin Oncol 1998; 17: 1482.
  • Chua DTT, Sham JST, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregjonally advanced nasopharyngeal carcinoma. Cancer 1998; 83: 2270-83.
  • Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-7.
  • Wong JR. Is chemotherapy beneficial in the treatment of locoregjonally advanced nasopharyngeal carcinoma? [Editorial]. Cancer 1998; 83: 2255-8.
  • Wei WI, Ho CM, Wong MP, Ng WF, Lau SK, Lam KH. Pathological basis of surgery in the management of postradiotherapy cervical metastasis in nasopharyngeal carcinoma Arch Otolaryngol Head Neck Surg 1992; 118:923-9.
  • Kwong DLW, Wei WI, Cheng ACK, et al. Long term results of radioactive gold grain implantation for the treatment of persistent and recurrent nasopharyngeal carcinoma Cancer 2001; 91: 1105-13.
  • Fee WE Jr, Roberson JB Jr, Goffinet DR. Long-term survival after surgical resection for recurrent nasopharyngeal cancer after radiotherapy failure. Arch Otolaryngol Head Neck Surg 1991; 117: 1233-6.
  • Wei WI. Salvage surgery for recurrent primary nasopharyngeal carcinoma. Crit Rev Oncol Hematol 2000; 33: 91-8.
  • Wei WI, Ho CM, Yuen PW, Fung CF, Sham JST, Lam KH. Maxillary swing approach for resection of tumors in and around the nasopharynx. Arch Otolaryngol Head Neck Surg 1995; 121: 638-42.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.